



April 18, 2026

David Lieber, MD
Blessing Corporate Services, Inc.

Dear Investigator,

SUBJECT: Notice of IBC Evaluation of Potential Research Modification

Sponsor: Ferring Pharmaceuticals A/S
Protocol: 000423 (ABLE-32)

Document Evaluated: • Clinical Trial Supply Manual, Version 4.0, dated 03-2026

An IBC Chair has determined that the changes in this document do not constitute a modification of the research per the NIH Guidelines, Section IV-B-7-a-(1). Further IBC review is not required before implementing these changes.

Please keep this notification for your records. Note that this document may have been previously reviewed and approved at a convened IBC meeting. For any questions or concerns, please contact WCG IBC Services at (360) 252-2850, or ibcservices@wcgclinical.com.

If you have changes to your research to submit, please complete an [IBC Change in Research Form](#), and submit the completed form to ibcservices@wcgclinical.com.

cc: Kiley McGlauchlen, MS, CCRP, Blessing Corporate Services, Inc.
Tim Tranor, Blessing Corporate Services, Inc.
Ashley Chbeir, Blessing Corporate Services, Inc.
Eric Martin, Blessing Corporate Services, Inc.
Spencer Kalk, Syneos Health
Amanda Carver, Syneos Health
Katie Robb, Syneos Health
Daniella Yoon, Syneos Health
Andy Walden, Syneos Health
Betsey Kapoor, Syneos Health
Natalie Amaral, Syneos Health
Manny Carmona, Syneos Health
Mykyta Kuzmin, Syneos Health
Study File